KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $145.0 million.

  • Regeneron Pharmaceuticals' Depreciation & Amortization (CF) rose 1471.52% to $145.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $543.7 million, marking a year-over-year increase of 1259.06%. This contributed to the annual value of $543.7 million for FY2025, which is 1259.06% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Depreciation & Amortization (CF) is $145.0 million, which was up 1471.52% from $136.7 million recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $145.0 million in Q4 2025 and a low of $67.4 million during Q1 2021
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $104.2 million (2023), whereas its average is $103.8 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 464.14% in 2022, then soared by 3857.53% in 2023.
  • Regeneron Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $74.5 million in 2021, then surged by 34.36% to $100.1 million in 2022, then grew by 12.89% to $113.0 million in 2023, then grew by 11.86% to $126.4 million in 2024, then increased by 14.72% to $145.0 million in 2025.
  • Its Depreciation & Amortization (CF) was $145.0 million in Q4 2025, compared to $136.7 million in Q3 2025 and $135.1 million in Q2 2025.